Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC

Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: SKIN Vehicle: ACETONE

| Study Summary | | | | | | | | | | |
|-----------------------------|-----------------|------------------------|----------------------------------|---|--|--|--------------------------------|--|--|--|
| Laboratory Name | Study Number | Study Start Date | Length of Study in Days | Number of Animals Total and (#/Cage) | Number Surviving and (Mean Life Span) | Maximum Mean Weekly Body Weight | Chemical | | | |
| | | | | | Male | | | | | |
| Southern Research Institute | 058813307 | 01/18/05 | 729 | 50(1) | 23(681) | 516.1 | Trimethylolpropane triacrylate | | | |
| | | | | | Female | | | | | |
| Southern Research Institute | 058813307 | 01/18/05 | 731 | 50(1) | 27(688) | 352.8 | Trimethylolpropane triacrylate | | | |

| Version: May2011 Contract/Lab: All Laboratori Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | Page: 315 Report Dat | age: 315 eport Date: 05/18/2011 | |
|--|-------|--------------|-----------|---|------------------|-------------|-------------------------|------------------------------------|--|
| | | | Male | | | Female | | | |
| #All Organs: Benign Tumors | | 48/50 (96%) | | | | 43/50 (86%) | | | |
| Overall Incidence | Total | 48/50 (96%) | Mean 96% | SD 0% | Total | 43/50 (86%) | Mean 86% | SD 0% | |
| #All Organs: Malignant Tumors | | 30/50 (60%) | | | | 21/50 (42%) | | | |
| Overall Incidence | Total | 30/50 (60%) | Mean 60% | SD 0% | Total | 21/50 (42%) | Mean 42% | SD 0% | |
| #All Organs: Malignant and Benign Tu | imors | 50/50 (100%) | | | | 47/50 (94%) | Marca 0494 | 05.0% | |
| Overall Incidence | Total | 50/50 (100%) | Mean 100% | SD 0% | Total | 47/50 (94%) | Mean 94% | SD 0% | |
| #All Organs: Hemangioma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #All Organs: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #All Organs: Hemangiosarcoma or He | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |

| Contract/Lab: All Laboratori Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONE | ol Animal Groups | | Page: 316 Report Dat | Page: 316 Report Date: 05/18/2011 | |
|---|---|--|---|---|-------------------------|---|-------------------------|--------------------------------------|--|
| | | | | Female | | | | | |
| #All Organs: Histiocytic Sarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #All Organs: Leukemia: Erythrocytic | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| Overall Incidence | Total | | | | | · · · · · · · · · · · · · · · · · · · | | | |
| #All Organs: Leukemia: Lymphocytic, | | | | | Total | 12/50 (24%) 12/50 (24%) | Mean 24% | SD 0% | |
| #All Organs: Leukemia: Lymphocytic, Overall Incidence #All Organs: Malignant Lymphoma: H | Monocytic, Mc Total | ononuclear, or Undifferen 26/50 (52%) 26/50 (52%) phocytic, Mixed, NOS, or 0/50 (0%) | tiated Mean 52% | SD 0% | Total | 12/50 (24%) 12/50 (24%) 0/50 (0%) | Mean 24% Mean 0% | SD 0% | |
| #All Organs: Leukemia: Lymphocytic, Overall Incidence #All Organs: | Monocytic, Mc Total istiocytic, Lym | ononuclear, or Undifferen 26/50 (52%) 26/50 (52%) phocytic, Mixed, NOS, or 0/50 (0%) 0/50 (0%) | tiated Mean 52% Undifferentiated Ce | SD 0% | Total | 12/50 (24%) 12/50 (24%) 0/50 (0%) 0/50 (0%) | | | |
| #All Organs: Leukemia: Lymphocytic, Overall Incidence #All Organs: Malignant Lymphoma: H Overall Incidence #All Organs: Mesothelioma: Benign Overall Incidence | Monocytic, Mc Total istiocytic, Lym Total Total | ononuclear, or Undifferen 26/50 (52%) 26/50 (52%) phocytic, Mixed, NOS, or 0/50 (0%) 0/50 (0%) 0/50 (0%) | tiated Mean 52% Undifferentiated Ce Mean 0% Mean 0% | SD 0% | Total Total Total | 12/50 (24%) 12/50 (24%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | Mean 0% Mean 0% | SD 0% SD 0% | |
| #All Organs: Leukemia: Lymphocytic, Overall Incidence #All Organs: Malignant Lymphoma: H Overall Incidence #All Organs: Mesothelioma: Benign | Monocytic, Mo Total istiocytic, Lym Total Total | ononuclear, or Undifferen 26/50 (52%) 26/50 (52%) phocytic, Mixed, NOS, or 0/50 (0%) 0/50 (0%) 0/50 (0%) | tiated Mean 52% Undifferentiated Ce Mean 0% Mean 0% | SD 0% | Total Total Total | 12/50 (24%) 12/50 (24%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | Mean 0% Mean 0% | SD 0% SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 317 Report Date: | | | | |
|--|-------|------------------------|---------|--|------------------|------------------------|---------------------------|-------|--|--|--|
| | | | Male | | | | Female | | | | |
| #All Organs: Mesothelioma: Malignant | | 0/50 (0%) | | | 0/50 (0%) | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #All Organs: Osteoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #All Organs: Osteosarcoma Overall Incidence | Total | 2/50 (4%) 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| #All Organs: Osteosarcoma or Osteoma | | 2/50 (4%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Adrenal Cortex: Adenoma | | 1/50 (2%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Adrenal Cortex: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | logy Data Manageme nce for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | e: 05/18/2011 | |
|--|--------------|--|-------------|--|------------------|------------------------|---------------|-------|
| | | | Male | | | Female | | |
| *Adrenal Medulla: Ganglioneuroma | | 0/49 (0%) | | 0/48 (0%) | | | | |
| Overall Incidence | Total | 0/49 (0%) | Mean 0% | SD 0% | Total | 0/48 (0%) | Mean 0% | SD 0% |
| *Adrenal Medulla: Hemangioma | | 0/49 (0%) | | | | 0/48 (0%) | | |
| Overall Incidence | Total | 0/49 (0%) | Mean 0% | SD 0% | Total | 0/48 (0%) | Mean 0% | SD 0% |
| *Adrenal Medulla: Pheochromocytoma Benign Overall Incidence | | 11/49 (22%) 11/49 (22.45%) | Mean 22.45% | SD 0% | Total | 0/48 (0%) 0/48 (0%) | Mean 0% | SD 0% |
| *Adrenal Medulla: Pheochromocytoma Comple | | () | | | | 0/48 (0%) | | |
| Overall Incidence | Total | 0/49 (0%) | Mean 0% | SD 0% | Total | 0/48 (0%) | Mean 0% | SD 0% |
| *Adrenal Medulla: Pheochromocytoma Malign | | 1/49 (2%) | | | | 0/48 (0%) | | |
| Overall Incidence | Total | 1/49 (2.04%) | Mean 2.04% | SD 0% | Total | 0/48 (0%) | Mean 0% | SD 0% |
| *Adrenal Medulla: Pheochromocytoma: Benig | | x, Malignant, NOS 12/49 (24%) | | | | 0/48 (0%) | | |
| Overall Incidence *: Denominator is number of animals #: Denominator is number of animals | with tissues | 12/49 (24.49%) examined microscopically | Mean 24.49% | SD 0% | Total | 0/48 (0%) | Mean 0% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | rol Animal Groups | | Page: 319 Report Dat | 9 ate: 05/18/2011 | |
|--|----------------|------------------------|---------|--|-------------------|------------------------|-------------------------|-----------------------------|--|
| | | | Male | | | Female | | | |
| #Bone: Chordoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Bone: Osteoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Bone: Osteosarcoma Overall Incidence | Total | 2/50 (4%) 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Bone: Osteosarcoma or Osteoma Overall Incidence | Total | 2/50 (4%) 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Astrocytoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Ependymoma Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *: Denominator is number of animals | with tissues e | | | | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | e: 05/18/2011 | | |
|--|-------|------------------------|---------|---|------------------|------------------------|----------------------|-------|--|
| | | | Male | | | | Female | | |
| *Brain: Ependymoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Glioma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Glioma Benign Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Glioma Malignant Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Granular Cell Tumor Benign | | · · / | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Brain: Oligodendroglioma Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | e: 05/18/2011 | |
|--|--------------------|------------------------|---------|--|------------------|------------------------|----------------------|-------|
| | | | Male | | | | Female | |
| *Brain: Oligodendroglioma Maligna Overall Incidence | nt Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| *Brain: | | | | | | | | |
| Oligodendroglioma, Glioma | , or Astrocy | toma 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Brain: Osteosarcoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| | | | | | | | | 50 0% |
| *Brain: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Clitoral/Preputial Gland: Adenoma | | 3/50 (6%) | | | | 4/50 (8%) | | |
| Overall Incidence | Total | 3/50 (6%) | Mean 6% | SD 0% | Total | 4/50 (8%) | Mean 8% | SD 0% |
| *Clitoral/Preputial Gland: Carcinoma | | 0/50 (0%) | | | | 7/50 (14%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 7/50 (14%) | Mean 14% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | blogy Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONE | ol Animal Groups | | e: 05/18/2011 | | | |
|--|-------|------------------------|---------|---|------------------|----------------------------|----------------------|-------|--|--|
| | | | Male | | | | Female | | | |
| *Clitoral/Preputial Gland: Carcinoma or Adenoma Overall Incidence | Total | 3/50 (6%) 3/50 (6%) | Mean 6% | SD 0% | Total | 10/50 (20%) 10/50 (20%) | | | | |
| | | 3/30 (078) | | JD 0% | 10181 | 10/30 (20%) | Mean 20% | SD 0% | | |
| *Clitoral/Preputial Gland: Sarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Ear: Neural Crest Tumor Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| #Esophagus: Lipoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| #Eye: Melanoma Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Eye: Melanoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 323 Report Dat | Page: 323 Report Date: 05/18/2011 | |
|--|-------|------------------------|---------|--|------------------|------------------------|-------------------------|--------------------------------------|--|
| | | | Male | | Female | | | | |
| #Eye: Schwannoma Malignant | | 0/50 (0%) | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Harderian Gland: Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Harderian Gland: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Harderian Gland: Carcinoma or Adenoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| | | 0,00 (0,0) | | | | 0,00 (0,0) | | | |
| *Heart: Schwannoma Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Heart: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | blogy Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | : 05/18/2011 | | | |
|--|-------|------------------------|---------|--|------------------|------------------------|--------------|-------|--|--|
| | | | Male | | Female | | | | | |
| #Intestine Large: Colon/Rectum: Adenoma | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| #Intestine Large: Colon/Rectu Carcinoma or Adenoma | | | | | | 0/50 (00/) | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| #Intestine Large: Colon/Rectu Hemangioma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Intestine Small: Duodenum: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Intestine Small: Duodenum: Leiomyoma | | | | | | 0/50 (00/) | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| #Intestine Small: Duodenum: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |

| Version: May2011 Contract/Lab: All Laboratorie Species: RATS Strain: F 344/N Length of Study: CHRONIC | 95 | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | e: 05/18/2011 | |
|---|-------|------------------------|---------|--|------------------|------------------------|----------------------|-------|
| | | | Male | | | Female | | |
| #Intestine Small: Ileum: Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Intestine Small: Jejunum: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Intestine Small: Jejunum: Granular Cell Tumor Mali Overall Incidence | | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| #Intestine Small: Jejunum: Leiomyoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Intestine Small: Jejunum: Leiomyosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Intestine Small: Site Unspo Adenoma | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 326 Report Date: 05/ | | | | |
|--|--------|------------------------|---------|--|------------------|------------------------|---|-------|--|--|--|
| | | | Male | | | | Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% SD 0% | | | | |
| #Intestine Small: Site Unspec Carcinoma | ified: | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Intestine Small: Site Unspec Carcinoma or Adenoma | ified: | 0/50 (00/) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Intestine Small: Site Unspec Granular Cell Tumor Maligi | ified: | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Intestine Small: Site Unspec Leiomyoma | ified: | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Intestine Small: Site Unspec Leiomyosarcoma | | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Intestine Small: Site Unspec Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratorie Species: RATS Strain: F 344/N Length of Study: CHRONIC | S | | | Route: SKIN | ol Animal Groups | | e: 05/18/2011 | | |
|---|----------------|------------------------|---|-------------|------------------|------------------------|----------------------|--------|--|
| | | | Male 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 0% SD 0% Total 0/50 (0%) 6) Mean 0% SD 0% Total 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 36% SD 0% Total 3/50 (6%) 6) Mean 0% SD 0% Total 0/50 (0%) | | | | Female | | |
| *Islets, Pancreatic: Adenoma | | 18/50 (36%) | | | | 3/50 (6%) | | | |
| Overall Incidence | Total | 18/50 (36%) | Mean 36% | SD 0% | Total | 3/50 (6%) | Mean 6% | SD 0% | |
| *Islets, Pancreatic: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | | | | 0/50 (0%) | Mean 0% | SD 0% | |
| *Islets, Pancreatic: Carcinoma or Adenoma | | 18/50 (36%) | | | | 3/50 (6%) | | 05.00/ | |
| Overall Incidence | Total | 18/50 (36%) | | SD 0% | l otal | 3/50 (6%) | Mean 6% | SD 0% | |
| *Kidney: Pelvis and Transiti Carcinoma | onal Epitheliu | m: 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | | | | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Pelvis and Transiti Carcinoma or Adenoma | | m: | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | | | | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Pelvis and Transiti Papilloma | | m: | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | Toxic Tumor Incide | Page: 328 Report Dat | Page: 328 Report Date: 05/18/2011 | | | | |
|--|--------------------|------------------------|------------------------------|-------------------------|--------------------------------------|------------------------|---------|-------|--|
| | | | Male | | | | Female | | |
| *Kidney: Renal Tubule: Adenoma | 0/50 (0%) 0/50 (0% | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Renal Tubule: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Renal Tubule: Carcinoma or Adenoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Renal Tubule: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Renal Tubule: Lipoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Kidney: Renal Tubule: Mesenchymal Tumor Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | 5 | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | Page: 329 Report Date: 05/18/2011 | | | | |
|--|-------|------------------------|---------|---|------------------|-----------|--|-------|--|--|--|
| | | | Male | | | | Female 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 1/50 (2%) 1/50 (2%) Mean 2% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% | | | | |
| *Kidney: Renal Tubule: Mesenchymal Tumor Malig | | 0/50 (0%) | | | | · · · | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | () | Mean 0% | SD 0% | | | |
| *Kidney: Renal Tubule: Nephroblastoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Kidney: Renal Tubule: Sarcoma | | 0/50 (0%) | | | | 1/50 (2%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% | | | |
| *Liver: Cholangioma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | () | Mean 0% | SD 0% | | | |
| | | 0,00 (0,0) | | | | | | | | | |
| *Liver: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | | | | | |
| *Liver: Hepatocellular Adenoma | | 1/50 (2%) | | | | | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 330 Report Date: 05 | | | | |
|--|--------------|---------------------------|---------|--|------------------|------------------------|---|-------|--|--|--|
| | | | Male | | | | Mean 0% SD 0% %) Mean 0% SD 0% %) Mean 0% SD 0% %) Mean 0% SD 0% | | | | |
| *Liver: Hepatocellular Carcinoma Overall Incidence | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| | | 1,00 (2,0) | | | | | | | | | |
| *Liver: Hepatocellular Carcinoma | or Hepatobla | stoma 1/50 (2%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Liver: Hepatocellular Carcinoma Overall Incidence | Total | 2/50 (4%) 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Liver: Hepatocellular Carcinoma, | | | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Liver: Ito Cell Tumor Benign | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Lung: Alveolar/Bronchiolar Aden | oma | 1/50 (2%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | Toxic a Tumor Incide | Page: 331 Report Date: 05/18/2011 | | | | | | | |
|--|-------|---------------------------------------|--------------------------------|--------------------------------------|-------|-----------|----------|--------|--|--|--|
| | | | Male | | | | - | | | | |
| | | | | | | | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | () | Mean 0% | SD 0% | | | |
| *Lung: Alveolar/Bronchiolar Carcin | | eolar/Bronchiolar Adenor 2/50 (4%) | | | | | | | | | |
| Overall Incidence | Total | 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Lung: Fibrosarcoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | () | Mean 0% | SD 0% | | | |
| *Lung: Hemangiosarcoma | | 0/50 (0%) | | CD 00/ | Tetel | . , | Maaa 00/ | CD 00/ | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | | wean 0% | SD 0% | | | |
| *Lung: Squamous Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | . , | Mean 0% | SD 0% | | | |
| #Lymph Node: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | e: 05/18/2011 | |
|--|-------|------------------------|-----------|--|------------------|----------------------------|---------------|-------|
| | | | Male | | | | Female | |
| #Mammary Gland: Adenolipoma | | 0/50 (0%) | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Mammary Gland: Adenoma | | 0/50 (0%) | | | | 4/50 (8%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 4/50 (8%) | Mean 8% | SD 0% |
| #Mammary Gland: Carcinoma | | 0/50 (0%) | | | | 3/50 (6%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 3/50 (6%) | Mean 6% | SD 0% |
| #Mammary Gland: Carcinoma or Adenoma | | 0/50 (0%) | | | | 6/50 (12%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 6/50 (12%) | Mean 12% | SD 0% |
| #Mammary Gland: Fibroadenoma | | | | | | | | |
| Overall Incidence | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | Total | 22/50 (44%) 22/50 (44%) | Mean 44% | SD 0% |
| #Mammary Gland: Fibroma | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | Page: 333 Report Date: 05/18/ | | | | |
|--|--------------|------------------------|---------|---|---|-------------|--|-------|--|--|--|
| | | | Male | | Pute: SKIN le: ACETONE Female 0% Total 25/50 (50%) 25/50 (50%) Mean 50% SD 0% 0% Total 25/50 (50%) Mean 50% SD 0% 0% Total 25/50 (50%) Mean 50% SD 0% 0% Total 0/50 (0%) Mean 50% SD 0% 0% Total 0/50 (0%) Mean 0% SD 0% | | | | | | |
| #Mammary Gland: Fibroma, Fibroadenoma or | Adenoma | 1/50 (2%) | | | | 25/50 (50%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | · · / | Mean 50% | SD 0% | | | |
| #Mammary Gland: Fibroma, Fibroadenoma, C | arcinoma, or | Adenoma 1/50 (2%) | | | | 25/50 (50%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | | 25/50 (50%) | | SD 0% | | | |
| #Mesentery: Fibrous Histiocytoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | 0/50 (0%) | | SD 0% | | | |
| #Mesentery: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | | () | Mean 0% | SD 0% | | | |
| #Mesentery: Lipoma | | 0/50 (0%) | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Mesentery: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | Page: 334 Report Date: 05/18/2011 | | | | | | | |
|--|------------------|---------------------------------------|--------------------------------------|--|-------|------------------------|---------|--------|--|--|
| | | | Male | Mean 0% SD 0% Total 0/50 (0%) 0/50 (0%) M Mean 0% SD 0% Total 0/50 (0%) M Mean 0% SD 0% Total 0/50 (0%) M Mean 2% SD 0% Total 0/50 (0%) M Mean 0% SD 0% Total 0/50 (0%) M Mean 0% SD 0% Total 0/50 (0%) M Mean 0% SD 0% Total 0/50 (0%) M Mean 2% SD 0% Total 0/50 (0%) M | | | Female | Female | | |
| *Nose: Adenoma | | 0/50 (0%) | | 0/50 (0%) | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | | Mean 0% | SD 0% | | |
| *Nose: Squamous Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | | | | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Oral Cavity (Oral Mucosa, To Papilloma Squamous or Pa Overall Incidence | ongue, Phar | | | | | 0/50 (0%) | Mean 0% | SD 0% | | |
| | | ····· | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | | SD 0% | Total | . , | Mean 0% | SD 0% | | |
| #Oral Cavity (Oral Mucosa, To Squamous Cell Carcinoma, | ongue, Phar | ynx, Tooth, Gingiva): | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 1/50 (2%) | | SD 0% | Total | · · · | Mean 0% | SD 0% | | |
| #Oral Mucosa: Squamous Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| *: Denominator is number of animals | s with tissues e | · · · · · · · · · · · · · · · · · · · | | | | 7 | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONE | ol Animal Groups | | Page: 335 Report Date: 05/18/2011 Female Mean 0% SD 0% | | | | |
|--|--------------|-------------------------|---------|---|------------------|------------------------|--|-------|--|--|--|
| | | | Male | | | | Female | | | | |
| #Oral Mucosa: Squamous Cell Papilloma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Ovary: Cystadenoma | | | | | | 0/50 (0%) | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Ovary: Fibrosarcoma | | | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Ovary: Granulosa Cell Tumor Benig | gn | | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| *Ovary: Granulosa Cell Tumor Malig | Inant | | | | | | | | | | |
| Overall Incidence | | | | | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | | | |
| *Ovary: Granulosa Cell Tumor: Beni | gn, Malignar | nt, NOS | | | | | | | | | |
| Overall Incidence | | | | | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | | | |
| *: Denominator is number of animals #: Denominator is number of animals | | kamined microscopically | | | | | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | 5 | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 336 Report Date: 05/18/2011 Female Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% | | |
|--|-----------|-----------|---------|--|------------------|------------|--|--------|--|
| · <i>· ·</i> | | | Male | | | | Female | | |
| *Ovary: Granulosa-Theca Tumor B | lonian | | | | | | | | |
| Granulosa-Theca Tunior B | lenign | | | | | 0/50 (0%) | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) | | | |
| *Ovary: Granulosa-Theca Tumor N | lalignant | | | | | | | | |
| | - | | | | | 0/50 (0%) | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Ovary: Schwannoma Malignant | | | | | | | | | |
| • • • • • • | | | | | T () | 0/50 (0%) | N. 00/ | 00.00/ | |
| Overall Incidence | | | | | Total | 0/50 (0%) | | | |
| *Ovary: Tubulostromal Adenoma | | | | | | | | | |
| . | | | | | T () | 0/50 (0%) | N. 00/ | 00.00/ | |
| Overall Incidence | | | | | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Pancreas: Adenoma | | | | | | | | | |
| | | 1/50 (2%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Pancreas: Carcinoma | | | | | | 0/50 (00/) | | | |
| Overell Incidence | Total | 0/50 (0%) | Maan Ol | SD 0% | Total | 0/50 (0%) | Maan Ol | SD 00/ | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | logy Data Manageme nce for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 337 Report Dat | e: 05/18/2011 |
|--|----------------|-------------------------------|-------------|--|--|-------------|-------------------------|----------------------|
| | | | Male | | Female 0/50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /50 (0%) /650 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% 0/45 (0%) Mean 0% SD 0% 6/50 (72%) | | | |
| *Pancreas: Carcinoma or Adenoma | | 1/50 (2%) | | | | |) | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Pancreas: Mixed Tumor Benign | | 1/50 (2%) | | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | | |
| *Pancreas: Mixed Tumor Malignant Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | | | |
| *Parathyroid Gland: Adenoma | | 0/45 (0%) | | | | 0/45 (0%) | | |
| Overall Incidence | Total | 0/45 (0%) | Mean 0% | SD 0% | Total | 0/45 (0%) | Mean 0% | SD 0% |
| *Pituitary Gland: Pars Distalis Adenoma | | | | | | | | |
| Overall Incidence | Total | 34/49 (69%) 34/49 (69.39%) | Mean 69.39% | SD 0% | Total | 36/50 (72%) | | |
| *Pituitary Gland: Pars Distalis Carcinoma | | | | | | | | |
| O | T . () | 0/49 (0%) | Mara 00/ | | - | 2/50 (4%) | Maga 10/ | OD 001 |
| Overall Incidence | Total | 0/49 (0%) | Mean 0% | SD 0% | Total | 2/50 (4%) | Mean 4% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | logy Data Manageme nce for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 338 Report Date: 05/18/2011 Female Mean 76% SD 0% Mean 0% SD 0% | | | |
|--|-------------|------------------------|-------------|--|------------------|------------------------|---|-------|--|--|
| | | | Male | | | | Female Mean 76% SD 0% | | | |
| *Pituitary Gland: Pars Distalis Carcinoma or Adenoma | s or Unspec | ified Site: | | | | | | | | |
| | | 34/49 (69%) | | | | 38/50 (76%) | | | | |
| Overall Incidence | Total | 34/49 (69.39%) | Mean 69.39% | SD 0% | Total | 38/50 (76%) | Mean 76% | SD 0% | | |
| *Pituitary Gland: Pars Distalis Ganglioneuroma | | cified Site: | | | | | | | | |
| Overall Incidence | Total | 0/49 (0%) 0/49 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| | | | | | | | | | | |
| *Pituitary Gland: Pars Intermo Adenoma | edia: | 0/40 (00/) | | | | | | | | |
| Overall Incidence | Total | 0/49 (0%) 0/49 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | | |
| *Pituitary Gland: Pars Intermo Carcinoma or Adenoma | | | | | | | | | | |
| Overall Incidence | Total | 0/49 (0%) 0/49 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | | |
| Pituitary Gland: Pars Nervos Craniopharyngioma | a: | | | | | | | | | |
| | | 0/49 (0%) | | | | 1/50 (2%) | | | | |
| Overall Incidence | Total | 0/49 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% | | |
| *Prostate: Adenoma | | | | | | | | | | |
| | | 0/50 (0%) | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 339 Report Dat | e: 05/18/2011 | |
|--|-------|------------------------|---------|--|------------------|-----------|---|----------------------|--|
| | | | Male | | | | Female 0/50 (0%) 0/50 (0%) Mean 0% SD 0% 0/50 (0%) 0/50 (0%) Mean 0% SD 0% | | |
| *Prostate: Carcinoma or Adenoma | | 0/50 (0%) | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | | | | | |
| *Salivary Glands: Carcinoma | | 1/50 (2%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | | Mean 0% | SD 0% | |
| *Salivary Glands: Carcinoma or Adenoma Overall Incidence | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | Total | · · · | Mean 0% | SD 0% | |
| *Salivary Glands: Sarcoma | | 0/50 (0%) | | | | () | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| *Salivary Glands: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | . , | Mean 0% | SD 0% | |
| #Seminal Vesicle: Adenoma | | 0/50 (0%) | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: SKIN Vehicle: ACETONE | | | | | Page: 340 Report Date: 05/18/2011 | | |
|--|--------------------|--|---------|-------|--------|--|--------------------------------------|-------|--|
| | | | Male | | | Female Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% | | | |
| #Skeletal Muscle: Fibrous Histiocytoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Moon 0% | SD 0% | |
| | | 0/30 (0%) | | | 1 Utai | 0/30 (078) | | 50 0% | |
| #Skeletal Muscle: Hemangiosarcoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Skeletal Muscle: Rhabdomyosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |
| #Skeletal Muscle: Rhabdomyosarcoma or Rha Overall Incidence | abdomyoma Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| | 10tai | 0/30 (076) | | 30 0% | Totai | 0/50 (078) | | 50 0% | |
| #Skin: Basal Cell Adenoma | | 0/50 (0%) | | | | 1/50 (2%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% | |
| #Skin: Basal Cell Adenoma or Bas | | | | | | 1/50 (2%) | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% | |
| *: Denominator is number of animals | with tissues ex | | | | | | | | |

| Version: May2011 Contract/Lab: All Laboratori Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: SKIN Vehicle: ACETONE | | | | Page: 341 Report Date: 05/18/2011 Female | | | | - | | |
|--|-----------------|--------------------------|----------------------|--|-------|------------------------|--|--|--|--|--|---|--|--|
| | | | Male | | | | Report Date: 05/18/2011 Female Mean 2% SD 0% | | | | | | | |
| #Skin: Basal Cell Adenoma, Basosquamous Tumor Benign, or Trichoepithelioma 0/50 (0%) 1/50 (2%) | | | | | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | | | | | | | | |
| Skin: Basal Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | | | | |
| ∜Skin: Basal Cell Carcinoma or Dverall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | | | | |
| Skin: Basal Cell Carcinoma, Ba NOS), or Trichoepithelior | asal Cell Adenc | oma, Basosquamous Tur | | | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | | | | | | |
| ≮Skin: Basal or Sq. Cell Carcino Adenoma, Papilloma, Sq | oma, Carcinoma | a, Basosq. Tumor (M or I | 3), Basal Cell Adeno | | | 1/50 (2%) | | | | | | | | |
| Overall Incidence | Total | 5/50 (10%) | Mean 10% | SD 0% | Total | 1/50 (2%) | | | | | | | | |
| Skin: Fibroma | | | | | | | | | | | | | | |
| | | 4/50 (8%) 4/50 (8%) | Mean 8% | | Total | 0/50 (0%) 0/50 (0%) | | | | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 342 Report Date: 05/18/2011 Female Mean 0% SD 0% Mean 0% SD 0% | | | |
|--|-------|------------------------|---------|--|------------------|------------------------|--|-------|--|--|
| | | | Male | | | | Female Mean 0% SD 0% | | | |
| #Skin: Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma 4/50 (8%) Overall Incidence Total 4/50 (8%) SD 0% Total 0/50 (0%) Mean 0% SD 0% | | | | | | | | | | |
| Overall Incidence | Total | 4/50 (8%) | Mean 8% | SD 0% | Total | 0/50 (0%) | | | | |
| #Skin: Fibrosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Skin: Fibrosarcoma, Sarcoma, My Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | | | | |
| #Skin: Fibrous Histiocytoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Skin: Hemangioma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Skin: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | Page: 343 Report Dat | e: 05/18/2011 |
|--|-----------------|------------------------|----------|---|------------------|------------------------|--|---------------|
| | | | Male | | | | Female Mean 0% SD 0% Mean 0% SD 0% | |
| #Skin: Keratoacanthoma Overall Incidence | Total | 4/50 (8%) 4/50 (8%) | Mean 8% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Moon 0% | SD 0% |
| | 10lai | 4/50 (6%) | | 30 0% | TOLAI | 0/50 (0%) | | 30 0% |
| #Skin: Lipoma | T -1-1 | 2/50 (4%) | Mara 40/ | 05.004 | Tatal | 0/50 (0%) | Mara 00/ | |
| Overall Incidence | Total | 2/50 (4%) | Mean 4% | SD 0% | Total | 0/50 (0%) | | |
| #Skin: Liposarcoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| #Skin: Neural Crest Tumor Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| #Skin: Neural Crest Tumor, Maligna | ant | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| #Skin: Neurofibroma or Schwanno | | 0/50 (0%) | | | | 1/50 (2%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% |
| *: Denominator is number of animals | with tissues ex | | | | | | | |

| Version: May2011 Contract/Lab: All Laboratorie Species: RATS Strain: F 344/N Length of Study: CHRONIC | S | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 344 Report Date: 05/18/2011 Female Mean 0% SD 0% | | | | |
|---|----------------|------------------------------------|-----------------|--|------------------|-----------|--|-------|--|--|--|
| | | | Male | | | | Female Mean 0% SD 0% Mean 2% SD 0% Mean 0% SD 0% Mean 2% SD 0% Mean 2% SD 0% Mean 2% SD 0% Mean 0% SD 0% Mean 0% SD 0% | | | | |
| #Skin: Neurofibrosarcoma or Schwannoma (malignant or NOS) 0/50 (0%) 0/50 (0%) 0/50 (0%) Overall Incidence Total 0/50 (0%) SD 0% Total 0/50 (0%) | | | | | | | | | | | |
| | | 0/30 (0%) | | | | | | 30 0% | | | |
| #Skin: Neurofibrosarcoma, Neuro | ofibroma, or S | chwannoma (benign, ma 0/50 (0%) | lignant or NOS) | | | 1/50 (2%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | | | | | |
| #Skin: Sarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Skin: Schwannoma Benign | | 0/50 (0%) | | | | 1/50 (2%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 1/50 (2%) | Mean 2% | SD 0% | | | |
| #Skin: Schwannoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | | | | | |
| #Skin: Squamous Cell Carcinom | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratorie: Species: RATS Strain: F 344/N Length of Study: CHRONIC | s | | | nce for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 345 Report Date: 05/18/2011 Female Mean 0% SD 0% | | | | |
|--|--------------|------------------------|----------|--|------------------|------------------------|---|-------|--|--|--|
| | | | Male | | | | Female | | | | |
| #Skin: Squamous Cell Carcinoma, Basal Cell Carcinoma, Basosquamous Tumor (malignant or NOS), or Carcinoma | | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| Skin: Squamous Cell Papilloma | | | | | | | | | | | |
| Overall Incidence | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | | |
| fSkin: Squamous Cell Papilloma | or Papilloma | 1/50 (2%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| Skin: Squamous Cell Papilloma | | | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 5/50 (10%) | Mean 10% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| fSkin: Squamous Cell Papilloma | | | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 5/50 (10%) | Mean 10% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| ∜Skin: Trichoepithelioma | | | | | | | | | | | |
| | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 346 Report Dat | e: 05/18/2011 |
|--|-------|------------------------|---------|--|------------------|--|-------------------------|----------------------|
| | | | Male | | | Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% | | |
| #Skin: Sebaceous Gland: Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Skin: Sebaceous Gland: Carcinoma or Adenoma | | 0/50 (0%) | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | | |
| #Spinal Cord: Astrocytoma Benign Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | | |
| fSpinal Cord: Astrocytoma Malignant Dverall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| Spinal Cord: Glioma Malignant Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| | | . , | | | | . , | | |
| Spleen: Fibrosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 347 Report Date: 05/18/2011 Female Mean 0% SD 0% Mean 0% SD 0% | | | |
|--|-------|---------------------------------------|---------|--|------------------|------------------------|--|-------|--|--|
| | | · · · · · · · · · · · · · · · · · · · | Male | | | | Female 0/50 (0%) Mean 0% SD 0% 0/50 (0%) Mean 0% SD 0% | | | |
| *Spleen: Fibrous Histiocytoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| *Spleen: | | · · · · · · · · · · · · · · · · · · · | | | | | | | | |
| Hemangiosarcoma | | 0/50 (00() | | | | 0/50 (00() | | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |
| *Spleen: Leiomyosarcoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | · · · | Mean 0% | SD 0% | | |
| | 10181 | 0/30 (078) | | | Total | 0/30 (078) | | 50 0% | | |
| *Spleen: Sarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Stomach, Forestomach: Leiomyosarcoma | | 0/50 (0%) | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Stomach, Forestomach: Squamous Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | Page: 348 Report Date: 05/18/2011 Female | | | | | | |
|--|-------|------------------------|---------|--|--|------------------------|--|-------|--|--|--|
| | | | Male | | | | Female Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% Mean 0% SD 0% | | | | |
| #Stomach, Forestomach: Squamous Cell Carcinoma or Papilloma Squamous 0/50 (0%) 0/50 (0%) 0/50 (0%) | | | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Stomach, Forestomach: Squamous Cell Papilloma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Stomach, Glandular: Carcinoma Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Moon 0% | SD 0% | | | |
| | | | | 50 0% | TOLAI | 0/50 (0%) | | 30 0% | | | |
| #Stomach, Glandular: Carcinoma or Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Stomach, Glandular: Lipoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |
| #Stomach, Glandular: Sarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | 3 | | | Route: SKIN | ol Animal Groups | | Page: 349 Report Dat | Report Date: 05/18/2011 Female | | | |
|--|-------|------------------------|-----------|--|------------------|-----------|-------------------------|--------------------------------|--|--|--|
| | | | Male | Male Oldstring Old | | | Female | | | | |
| *Testes: Adenoma | | 27/50 (54%) | | | | | | | | | |
| Overall Incidence | Total | 27/50 (54%) | Mean 54% | SD 0% | | | | | | | |
| *Testes: Hemangioma | | 0/50 (0%) | | | | | | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | | | | | | | |
| *Thymus: Thymoma Benign | | 0/45 (0%) | | | | () | | | | | |
| Overall Incidence | Total | 0/45 (0%) | Mean 0% | | | 0/47 (0%) | Mean 0% | SD 0% | | | |
| *Thymus: Thymoma Malignant | Tatal | 0/45 (0%) | Magar 00/ | | Total | · · · | Maga 00/ | SD 00/ | | | |
| Overall Incidence | Total | 0/45 (0%) | Mean 0% | SD 0% | l otal | 0/47 (0%) | Mean 0% | SD 0% | | | |
| *Thymus: Thymoma NOS | | 0/45 (0%) | | | | 0/47 (0%) | | | | | |
| Overall Incidence | Total | 0/45 (0%) | Mean 0% | | | 0/47 (0%) | Mean 0% | SD 0% | | | |
| *Thymus: Thymoma: Benign, Malign | | 0/45 (0%) | | | | 0/47 (0%) | | | | | |
| Overall Incidence | Total | 0/45 (0%) 0/45 (0%) | Mean 0% | SD 0% | Total | 0/47 (0%) | Mean 0% | SD 0% | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETONI | ol Animal Groups | | Page: 350 Report Dat | e: 05/18/2011 |
|--|-------|------------|----------|---|------------------|-----------|-------------------------|----------------------|
| | | | Male | | | | Female | |
| *Thyroid Gland: C-Cell: Adenoma | | 8/50 (16%) | | | | 3/50 (6%) | | |
| Overall Incidence | Total | 8/50 (16%) | Mean 16% | SD 0% | Total | 3/50 (6%) | Mean 6% | SD 0% |
| *Thyroid Gland: C-Cell: Carcinoma | | 1/50 (2%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Thyroid Gland: C-Cell: Carcinoma or Adenoma | | 8/50 (16%) | | | | 3/50 (6%) | | |
| Overall Incidence | Total | 8/50 (16%) | Mean 16% | SD 0% | Total | 3/50 (6%) | Mean 6% | SD 0% |
| *Thyroid Gland: Follicular Cell Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Thyroid Gland: Follicular Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |
| *Thyroid Gland: Follicular Cell Carcinoma or Adenoma | | 0/50 (0%) | | | | 0/50 (0%) | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: SKIN Vehicle: ACETONE | | | | | | Page: 351 Report Date: 05/18/2011 | | |
|--|--------------|--|---------|--------|-------|-----------|---------|--------------------------------------|--|--|
| | | | Male | Female | | | | | | |
| #Tissue NOS: Paraganglioma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Tongue: Squamous Cell Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Tongue: Squamous Cell Carcinoma | or Papilloma | a Squamous 1/50 (2%) | | | | 0/50 (0%) | | CD 00/ | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Tongue: Squamous Cell Papilloma | | 1/50 (2%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Tooth: Adamantinoma Malignant | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Tooth: Odontoma | | | | | | | | | | |
| | | 0/50 (0%) 0/50 (0%) | | | | 0/50 (0%) | | | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | Toxicology Data Management System Tumor Incidence for Selected Control Animal Groups Route: SKIN Vehicle: ACETONE | | | | | | Page: 352 Report Date: 05/18/2011 | | |
|--|-------|--|---------|-------|-------|------------------------|---------|--------------------------------------|--|--|
| | | | Male | | | | Female | | | |
| *Urinary Bladder: Carcinoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| *Urinary Bladder: Carcinoma or Papilloma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| *Urinary Bladder: Hemangiosarcoma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| *Urinary Bladder: Papilloma | | 0/50 (0%) | | | | 0/50 (0%) | | | | |
| Overall Incidence | Total | 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Uterus: Adenoma | | | | | | 0/50 (0%) | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) | Mean 0% | SD 0% | | |
| #Uterus: Carcinoma | | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | Toxicology Data Management Syste Tumor Incidence for Selected Control Anima Route: SKIN Vehicle: ACETONE | | | Page: 353 Report Dat | e: 05/18/2011 |
|--|---|-------|--------------------------|-------------------------|----------------------|
| | Male | | | Female | |
| #Uterus: Deciduoma Benign | | | 0/50 (0%) | Maar 00/ | CD 00/ |
| Overall Incidence | | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Uterus: Leiomyosarcoma | | | 0/50 (0%) | | |
| Overall Incidence | | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Uterus: Polyp Stromal | | | 9/50 (18%) | | 05.0% |
| Overall Incidence | | Total | 9/50 (18%) | Mean 18% | SD 0% |
| #Uterus: Sarcoma | | | 0/50 (0%) | | |
| Overall Incidence | | Total | 0/50 (0%) | Mean 0% | SD 0% |
| #Uterus: Sarcoma Stromal | | | | | |
| Overall Incidence | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% |
| #Uterus: Sarcoma Stromal or Polyp Stromal | | | | | |
| Overall Incidence *: Denominator is number of animals with tissues examined micro | | Total | 9/50 (18%) 9/50 (18%) | Mean 18% | SD 0% |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N | | | | ology Data Managem Ince for Selected Cont Route: SKIN Vehicle: ACETON | rol Animal Groups | Page: 354 Report Date: 05/18/2011 | | | |
|--|-------|------------------------|---------|--|-------------------|--------------------------------------|---------|-------|--|
| Length of Study: CHRONIC | | | | | | | | | |
| | | | Male | | | | Female | | |
| #Uterus: Schwannoma Malignant | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Vagina: Polyp | | | | | | 4/50 (00/) | | | |
| Overall Incidence | | | | | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | |
| #Vagina: Sarcoma | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Vagina: Schwannoma Malignant | | | | | | | | | |
| Overall Incidence | | | | | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Zymbal's Gland: Adenoma | | | | | | | | | |
| Overall Incidence | Total | 1/50 (2%) 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |
| #Zymbal's Gland: Carcinoma | | 0/50 (001) | | | | 0/50 (001) | | | |
| Overall Incidence | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | Total | 0/50 (0%) 0/50 (0%) | Mean 0% | SD 0% | |

| Version: May2011 Contract/Lab: All Laboratories Species: RATS Strain: F 344/N Length of Study: CHRONIC | | | | ology Data Manageme ence for Selected Contr Route: SKIN Vehicle: ACETON | ol Animal Groups | | Page: 355 Report Date: 05/18/2011 | | |
|--|-------|-----------|---------|--|------------------|-----------|--------------------------------------|-------|--|
| | | | Male | | | | Female | | |
| #Zymbal's Gland: Carcinoma or Adenoma | | 1/50 (2%) | | | | 0/50 (0%) | | | |
| Overall Incidence | Total | 1/50 (2%) | Mean 2% | SD 0% | Total | 0/50 (0%) | Mean 0% | SD 0% | |